Indivior Pharmaceuticals (INDV) Interest Expenses (2022 - 2026)

Indivior Pharmaceuticals' Interest Expenses history runs 5 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 16.67% year-over-year to $14.0 million in Q1 2026; TTM through Mar 2026 was $14.0 million, a 68.89% decrease from a year earlier, with the FY2025 full-year figure at $55.0 million, up 17.02% from the prior year.
• Interest Expenses advanced to $14.0 million in Q1 2026 per INDV's latest filing, from $6.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $28.0 million in Q4 2023 and bottomed at $6.0 million in Q4 2025.
• The 5-year median for Interest Expenses is $12.0 million (2025), against an average of $13.8 million.
• Biggest YoY gain for Interest Expenses was 66.67% in 2025; the steepest drop was 53.85% in 2025.
• Year by year, Interest Expenses stood at $23.0 million in 2022, then advanced by 21.74% to $28.0 million in 2023, then tumbled by 53.57% to $13.0 million in 2024, then slumped by 53.85% to $6.0 million in 2025, then jumped by 133.33% to $14.0 million in 2026.
• Per Business Quant, the three latest INDV Interest Expenses figures stand at $14.0 million (Q1 2026), $6.0 million (Q4 2025), and $12.0 million (Q3 2025).